Abstract
Myeloproliferative neoplasms (MPNs) are clonal bone marrow (BM) proliferations that most often manifest as increased peripheral blood (PB) counts and/or splenomegaly. Unlike myelodysplastic syndromes, the hemopoiesis in MPN is effective, leading to the increased peripheral counts; unlike the acute leukemias, there is intact maturation of all hematopoietic lineages. The main MPN entities discussed in this chapter are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The uncommon MPN entities of chronic neutrophilic leukemia and unclassifiable MPN are also discussed. An activating point mutation in the JAK2 gene underlies the pathogenesis of many MPN, including almost all cases of polycythemia vera and about half of essential thrombocythemia and primary myelofibrosis cases. Accurate diagnosis of MPN involves distinguishing these neoplasms from reactive causes of increased PB counts as well as appropriate classification of MPN into specific entities. The diagnosis of MPN requires an integration of clinical features, BM morphology, and genetic tests, in particular JAK2 mutation analysis. Therapeutic approaches, including targeted therapy as pertinent, are also discussed for each entity.
Keywords: Myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic idiopathic myelofibrosis, myeloid metaplasia, chronic neutrophilic leukemia, JAK2
Current Cancer Therapy Reviews
Title: Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Volume: 8 Issue: 1
Author(s): Robert P. Hasserjian
Affiliation:
Keywords: Myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic idiopathic myelofibrosis, myeloid metaplasia, chronic neutrophilic leukemia, JAK2
Abstract: Myeloproliferative neoplasms (MPNs) are clonal bone marrow (BM) proliferations that most often manifest as increased peripheral blood (PB) counts and/or splenomegaly. Unlike myelodysplastic syndromes, the hemopoiesis in MPN is effective, leading to the increased peripheral counts; unlike the acute leukemias, there is intact maturation of all hematopoietic lineages. The main MPN entities discussed in this chapter are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The uncommon MPN entities of chronic neutrophilic leukemia and unclassifiable MPN are also discussed. An activating point mutation in the JAK2 gene underlies the pathogenesis of many MPN, including almost all cases of polycythemia vera and about half of essential thrombocythemia and primary myelofibrosis cases. Accurate diagnosis of MPN involves distinguishing these neoplasms from reactive causes of increased PB counts as well as appropriate classification of MPN into specific entities. The diagnosis of MPN requires an integration of clinical features, BM morphology, and genetic tests, in particular JAK2 mutation analysis. Therapeutic approaches, including targeted therapy as pertinent, are also discussed for each entity.
Export Options
About this article
Cite this article as:
P. Hasserjian Robert, Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462495
DOI https://dx.doi.org/10.2174/157339412799462495 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets SUMOylation Regulation of Retina Development and Functions
Current Molecular Medicine Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Characteristic Alterations of Nuclear Structure and Chromatin Organisation of Cancer Cells Addressed by Proteome Analysis**
Current Proteomics Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery Genetic Manipulation of Human Embryonic Stem Cells: A System to Study Early Human Development and Potential Therapeutic Applications
Current Gene Therapy Leukaemia Infection Diagnosis and Intestinal Flora Disorder
Current Molecular Medicine The Heterogeneity of Glioma Stem Cells
Current Signal Transduction Therapy Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Quinoline-3-carboxylate Derivatives: A New Hope as an Antiproliferative Agent
Anti-Cancer Agents in Medicinal Chemistry Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Modelling and Measuring Redox Cycling and Cytotoxicity of Quinones
Drug Metabolism Letters Aminopeptidases of Malaria Parasites: New Targets for Chemotherapy
Infectious Disorders - Drug Targets